ENVVENO MEDICAL CORP (NVNO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$11.10-3.39%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Reduce operating losses and cash flow burn: metric not reported.
enVVeno has a new patent that helps its key valve study. The company aims for $25 million revenue by September 2026. Operating losses and cash burn have improved recently. Cash reserves of $28 million support ongoing work.
The company still loses money and burns cash. FDA approvals face delays and setbacks. Revenue is small and uncertain. The stock faces high risk and weak quality.
The market sees enVVeno as a risky, loss-making firm with uncertain growth. Our view is cautious but notes some progress on patents and study milestones.
Breaks if: Pivotal study progress stalls or FDA approval is delayed beyond 2026-Q3
Focus on progressing the FDA-approved Investigational Device Exemption application and pivotal study for the TAVVE device.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is mixed, reflecting both potential upside from sector momentum and significant operational challenges.
The market seems to have priced in a high level of uncertainty, given NVNO's loss-making status and the elevated risk of earnings misses. Expectations may be tempered by the company's recent mixed performance and ongoing litigation.
Fundamentals are likely to show limited improvement in managing operating losses and cash flow burn, as progress has been slow. The near-term risk of an earnings miss is elevated, which could impact investor sentiment.
The thesis hinges on NVNO's ability to advance its pivotal study and manage cash flow effectively. Additionally, external factors such as the performance of sector bellwethers and overall economic conditions will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls significantly below $25 million by 2026-Q3
Breaks if: Cash and investments fall below $28 million
Preserve cash and investment balances to fund ongoing clinical development and operations.
Newly stated in 2026-Q1. The company reported a cash and investments balance of approximately $28 million as of December 31, 2025. No subsequent updates on cash balances are provided, so the priority is stated but delivery on maintaining or growing cash reserves is not yet measurable.
“As of December 31, 2025, the Company had a cash and investments balance of approximately $28 million.”
Breaks if: Operating losses or cash burn worsen beyond 2026-Q1 levels
Continue to manage operating losses and negative cash flow from operations while progressing clinical and regulatory milestones.
Stated as a priority in 8 of last 8 quarters. Operating losses improved from negative $6.70M in 2024-Q4 to negative $4.06M in 2026-Q1, and cash flow burn improved from negative $5.11M to negative $3.24M over the same period. The trajectory shows limited progress in reducing losses and cash burn but consistent focus on managing these operational challenges.
“Operating income was negative $4.06M and cash from operations negative $3.24M.”
“Operating income was negative $4.01M and cash from operations negative $3.44M.”
“Operating income was negative $4.88M and cash from operations negative $4.39M.”
“Operating income was negative $7.05M and cash from operations negative $3.72M.”
“Operating income was negative $4.95M and cash from operations negative $4.02M.”
“Operating income was negative $6.70M and cash from operations negative $5.11M.”
“Operating income was negative $6.17M and cash from operations negative $4.28M.”
“Operating income was negative $5.45M and cash from operations negative $3.91M.”
In the next 1 to 3 years, NVNO's performance will depend on its operational execution and broader sector trends. Not investment advice.